Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Related parties (Details)

v3.8.0.1
Summary of Significant Accounting Policies - Related parties (Details) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Related parties    
Research and Development Expense $ 25,732,000 $ 18,615,000
Immunocore    
Related parties    
Research and Development Expense   $ 536,000